



Founded in 2018
Berkeley, California
5 Employees

The Brain Health Toolkit

Significant Unmet need: Objective markers to diagnose and monitor elusive and non-specific cognitive and mood symptoms in neurological and psychological diseases.

Large Market Opportunity: We estimate the TAM for Adult and Pediatric Screening and Monitoring of Epilepsy, ADHD, Mood to be \$13.7B.

Funding to date: \$4.7M

- Pre-Seed: \$1.9M Dilutive - UCB Pharma (Strategic)
- Non-Dilutive: \$3 Non-Dilutive: NIH, NSF

Value Creation Milestones Achieved

Initial Traction: 1st Product released as FDA Class 1 SaMD; Revenue Secured from 6 clinics, 2 enterprise hospitals; Proven Profitable Reimbursement; Strategic Partnership with UCB pharma; In contracting with 6 additional sites; 2 Term Sheets with prospective partners

Current Raise Pre Seed+ Round: \$2M Traunch (\$500K from NSF)

Target Value Creation Milestones: 2 Enterprise Hospitals (40 clinics) and 20 Private Clinics Installed, \$1.1M ARR; Release Attention App; Secure 2 partners; Secure \$3M in non-dilutive funding;

Capital Efficiency:

- Anticipated Path to Exit: 5 years
- MOIC: 35x (assuming 5x multiple)

MANAGEMENT TEAM / BOARD:

- CEO: Rachel Kuperman, MD 10+ years Director UCSF Benioff Children's Hospital Epilepsy Center
- COO: Parth Amin 20+ years Med Device; Product Development and Partnerships – Siemens Healthineers and Varian Medical Systems
- CTO: Jit Sarkar, PhD 15+ years AI/ML software development; UCSD Oceanography, DoD and Naval Research.
- BOD: Randy Berholz (Independent), Colin Lake (Observer)
- KOLs and Advisors: Robert Fisher, MD/PhD, Stanford; Hal Blumenfeld, MD/PhD, Yale; Peter Milford, PhD (Technical), Tracey Fisher, MBA (GTM), Keith La Plain (Commercialization)

EXECUTIVE SUMMARY:

Eysz is transforming neurological and psychiatric care with our Brain Health Platform, which leverages facial biometrics and AI on ubiquitous smartphones. This enables primary care physicians (PCPs) to diagnose and manage conditions like staring, inattention, depression, and anxiety effectively from their offices, facilitating early intervention and better outcomes. Our first product, an FDA Class 1 Software as a Medical Device (SaMD), allows PCPs to detect the most common childhood epilepsy early and in the context of ADHD care, reducing injuries and improving health and educational outcomes. Supported by rigorous clinical studies at top institutions and funded by NIH, NSF, and Jazz Pharma, our platform is also strengthened by a commercial partnership with UCB Pharma. Future products will expand our platform's capabilities, tapping into significant clinical need for objective neurological testing in both pediatric and adult patient care.

MARKET AND COMPETITION

Our digital health tool fills the gap for point-of-care decision-making to support PCPs in the implementation of AAP Guidelines on ADHD and a new revenue stream for PCPs through existing CPT codes. Unlike competitors like CHADIS and BrainCheck, which relies on digital cognitive assessment technologies, Eysz distinguishes itself with objective symptom measurement, independent of specific diseases, backed by robust peer-reviewed research. Through strategic partnerships, Eysz leads in integrating data and analytics, empowering pediatricians, neurologists, and mental health professionals to make quantitative determinations rapidly. This effectively addresses the critical need for objective markers in PCPs office to diagnose and monitor cognitive and mood-related symptoms initially in children and expanding to adults.

STRATEGY

We are launching our platform, initially targeting pediatric and neurology practices as our beachhead market. Additionally, we have launched a study backed by the NSF for attention and depression screening laying the groundwork to expand our platform. From screening we plan on going to monitoring, and from pediatrics we plan on going to adult – creating an additional >\$10B market opportunity. By fostering strategic partnerships and prioritizing collaborative customer relationships, our goal is to continuously increase value for our customers and our shareholders. Invest in our mission to deliver the brain health toolkit to clinicians who need objective markers to bring quantitative decision making to the field for the first time.